Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT1 | P17948 | 3/20 | 0.37 |
| ▸ | KDR | P35968 | 3/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.34 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.34 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.34 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.34 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.34 |
| ▸ | DHODH | Q02127 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22556368 | 0.85 | GSK3B (0.38) | FLT1KDRGSK3BABCG2KDM4E | |
| SCHEMBL23701613 | 0.85 | ABCG2 (0.41) | FLT1KDRGSK3BABCG2KDM4E | |
| SCHEMBL22556578 | 0.83 | FLT1 (0.40) | FLT1KDRGSK3BABCG2KDM4E | |
| SCHEMBL30463819 | 0.83 | FLT1 (0.40) | FLT1KDRGSK3BABCG2KDM4E | |
| SCHEMBL22556490 | 0.82 | FLT1 (0.39) | FLT1KDRGSK3BABCG2KDM4E | |
| SCHEMBL22556473 | 0.81 | ABCG2 (0.40) | FLT1KDRGSK3BABCG2KDM4E | |
| SCHEMBL22556395 | 0.80 | FLT1 (0.40) | FLT1KDRGSK3BABCG2KDM4E | |
| SCHEMBL22556299 | 0.80 | ABCG2 (0.44) | FLT1KDRGSK3BABCG2KDM4E | |
| SCHEMBL30463777 | 0.80 | ABCG2 (0.44) | FLT1KDRGSK3BABCG2KDM4E | |
| SCHEMBL25188053 | 0.80 | ABCG2 (0.39) | FLT1KDRGSK3BABCG2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-11661403-B2 | Oxadiazole compounds | VIVACE THERAPEUTICS, INC. (US) | 2023-05-30 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. | 2021-08-05 | — | — | US | disclosed |
| EP-3793551-A1 | OXADIAZOLE COMPOUNDS | Vivace Therapeutics, Inc. (US) | 2021-03-24 | — | — | EP | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
| WO-2019222431-A9 | OXADIAZOLE COMPOUNDS | VIVACE THERAPEUTICS, INC. (US) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238154-A1 | OXADIAZOLE COMPOUNDS | YAP1, TEAD2, TEAD3 | FLT1 2445/4885KDR 1811/4885GSK3B 193/4885 |
| US-11661403-B2 | Oxadiazole compounds | YAP1, TEAD2, TEAD3 | FLT1 2445/4885KDR 1811/4885GSK3B 193/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.